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ABSTRACT
Vertebral augmentation is among the current standards of care to reduce pain in patients with vertebral fractures (VF), yet a
lack of consensus regarding efficacy and safety of percutaneous vertebroplasty and kyphoplasty raises questions on what
basis clinicians should choose one therapy over another. Given the lack of consensus in the field, the American Society for
Bone and Mineral Research (ASBMR) leadership charged this Task Force to address key questions on the efficacy and safety of
vertebral augmentation and other nonpharmacological approaches for the treatment of pain after VF. This report details the
findings and recommendations of this Task Force. For patients with acutely painful VF, percutaneous vertebroplasty provides
no demonstrable clinically significant benefit over placebo. Results did not differ according to duration of pain. There is also
insufficient evidence to support kyphoplasty over nonsurgical management, percutaneous vertebroplasty, vertebral body
stenting, or KIVA®. There is limited evidence to determine the risk of incident VF or serious adverse effects (AE) related to
either percutaneous vertebroplasty or kyphoplasty. No recommendation can be made about harms, but they cannot be
excluded. For patients with painful VF, it is unclear whether spinal bracing improves physical function, disability, or quality of
life. Exercise may improve mobility and may reduce pain and fear of falling but does not reduce falls or fractures in individuals
with VF. General and intervention-specific research recommendations stress the need to reduce study bias and address
methodological flaws in study design and data collection. This includes the need for larger sample sizes, inclusion of a placebo
control, more data on serious AE, and more research on nonpharmacologic interventions. Routine use of vertebral
augmentation is not supported by current evidence. When it is offered, patients should be fully informed about the evidence.
Anti-osteoporotic medications must be initiated as soon as practicable, continued, or changed. © 2019 American Society for
Bone and Mineral Research.
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Executive Summary
Introduction
Vertebral compression fractures are highly prevalent in
patients with osteoporosis, and approximately 750,000 new
fractures occur each year in the United States alone.(1,2) Acute
and chronic back pain occur in approximately one-third of
patients with vertebral fractures, resulting in disability and
impaired quality of life. Vertebral augmentation (percutane-
ous vertebroplasty or balloon kyphoplasty) to reduce pain in
patients with symptomatic vertebral fractures was introduced
into practice before high-quality evidence establishing its
efficacy and safety and remains in some settings part of
standard routine care. Balloon kyphoplasty is currently more
expensive and is performed almost three times more
commonly than percutaneous vertebroplasty in the United
States.(3) Two placebo-controlled trials of percutaneous
vertebroplasty published in 2011 questioned the value of
this procedure, and an additional three trials, all in
participants with acute symptoms (for up to 9 weeks), have
now confirmed the findings of these earlier trials. No placebo-
controlled trials of balloon kyphoplasty have been performed
and evidence of the value of this procedure is reliant on low-
quality evidence from trials that have compared kyphoplasty
with usual care or head-to-head comparisons with vertebro-
plasty. In addition, there have been few trials of other
nonpharmacological approaches to reduce pain in patients
with vertebral fractures.
Task Force process
The American Society for Bone and Mineral Research (ASBMR)
leadership charged this Task Force to address key questions on
the efficacy and safety of vertebral augmentation and other
nonpharmacological approaches for the treatment of vertebral
fracture (Table 1). This report details the findings and
recommendations of this Task Force. The work of this report
builds upon that of a related ASBMR Task Force Report
published in 2017 that addressed pain, quality of life, and
safety outcomes associated with kyphoplasty for vertebral
fractures, which is summarized in detail in Section 2, Balloon
Kyphoplasty, below.(4)
The efficacy and safety of vertebral augmentation, either
percutaneous vertebroplasty or balloon kyphoplasty (Fig. 1),
and other nonpharmacologic treatments for painful vertebral
fractures, such as spinal bracing (Fig. 2), were assessed by a
systematic review of the existing literature and meta-analyses
(when appropriate) of outcomes including mean overall pain,
disability, disease-specific and overall health-related quality of
life, patient-reported treatment success, new symptomatic
vertebral fractures, and number of other serious adverse
events (AE) versus a comparator group, including placebo or a
sham procedure. Although new symptomatic vertebral
fractures after vertebral augmentation are considered a
harm, they could also represent a relapse of the primary
event related to osteoporosis. We included randomized
controlled trials (RCTs) and quasi-randomized trials that
enrolled adults aged >40 years with acute nontraumatic
vertebral fractures and directly compared percutaneous
vertebroplasty or balloon kyphoplasty versus any treatment
comparator group (eg, placebo, sham procedure, standard
medical care, exercise, manual therapy, braces, electrother-
apy, electro-acupuncture, percutaneous vertebroplasty, bal-
loon kyphoplasty, pharmacologic treatment, or other
nonpharmacologic intervention). Risk of bias was assessed
according to the Cochrane risk of bias tool. Important
considerations in interpreting trial data are timing of benefits
and harms of the interventions. Benefits such as improve-
ments in pain could be anticipated to occur early after an
intervention, while harms such as incident vertebral fractures,
could be anticipated to occur over both the shorter and
longer term.
Table 1. ASBMR Task Force Charges and Key Questions
Task Force charge Key questions addressed
Conduct systematic literature review, and meta-analysis if
appropriate, to address what is currently known and not known
about the safety and efficacy of vertebral augmentation,
including reviewing the evidence to assess if vertebral fracture
risk is increased after vertebral augmentation.
1. What is the efficacy and relative effectiveness of percutaneous
vertebroplasty in improving pain, physical function, and quality
of life?
2. What is the efficacy and relative effectiveness of balloon
kyphoplasty in improving pain, physical function, and quality of
life?
3. What are the harms of percutaneous vertebroplasty, including
possible risk of new vertebral fractures?
4. What are the harms of balloon kyphoplasty, including possible
risk of new vertebral fractures?
Consider the safety and efficacy of other nonpharmacologic
treatments for individuals with vertebral fracture, such as braces
and lumbar support corsets, transcutaneous electrical nerve
stimulation, and exercise programs, and compare them to
vertebral augmentation.
5. What is the safety and efficacy of other nonpharmacologic
treatments, such as spinal bracing, after vertebral fracture?
6. What is the safety and efficacy of exercise interventions after
vertebral fracture?
Identify the key questions and knowledge gaps to offer a
research agenda that will determine the safety and efficacy of
vertebral augmentation, as well as other nonpharmacologic
approaches for the management of osteoporotic vertebral
fractures.
7. What research is needed to fill knowledge gaps to improve
patient outcomes in managing osteoporotic vertebral fractures,
either through vertebral augmentation or other
nonpharmacologic approaches?
4 EBELING ET AL. Journal of Bone and Mineral Research
For the nonsurgical interventions, we included RCTs and
quasi-randomized trials of bracing or exercise interventions with
similar enrollment criteria as noted above and compared the
treatment groups to all comparators, including placebo. For
each article identified, two reviewers independently extracted
data on study design, participant characteristics, intervention
characteristics, outcomes, and AE. Risk of bias was rated as high,
moderate, or low by two independent examiners, according to
the Cochrane risk of bias tool.
Overview of Task Force recommendations and findings
All Task Force members reviewed the final Task Force
recommendations and, based on responses to questionnaires,
the majority agreed on each recommendation for each of the
three interventions. Task Force recommendations and findings
are summarized in Table 2. Detailed methods of the systematic
reviews and meta-analyses may be found in the supplemental
pages of the ASBMR Task Force report. Task Force recom-
mendations for future research are summarized in Table 3.
Guidance for the clinical management of patients with acute
vertebral fracture, based on the recommendations and
findings of the Task Force, is also offered, despite not being
a Task Force charge, nor a key question, and this is also
summarized in Table 3.
Comparator procedures and blinding
In the context of vertebral augmentation, placebo is exactly the
same as the actual treatment, except for the active ingredient, ie,
injection of bone cement into the vertebra. A sham procedure
means that local anesthetic was administered to the skin and the
procedure was simulated. It is important for assessing true
efficacy that patients and outcome assessment be blinded to
reduce the risk of performance and detection bias. An
assessment of the success of blinding should also be
undertaken. Trials comparing augmentation to controls, such
as usual care, are at high risk of bias because of the risk of
performance and detection bias and overestimate the benefits
of augmentation procedures. This is essential for trials that
evaluate conditions with a favorable natural history and/or that
measure patient-reported outcomes, as this can control for the
effect of contextual factors (placebo, regression to the mean,
favorable natural history, eg, diminishing pain after a vertebral
fracture) to determine an intervention’s true effect (or true
efficacy). Results of studies for painful osteoporotic vertebral
fractures that do not include a placebo control and do not blind
participants and/or outcome assessment should be interpreted
with caution because they overestimate the treatment effect
(usually by around 25% to 30%). When evidence was only
available from trials that did not include a placebo control, it was
graded as low, with the corresponding strength of recommen-
dation being weak.
Conclusion
The recommendations by this Task Force are designed to help
provide a foundation for advancing the research and clinical
care of patients with painful acute vertebral fractures. The
current evidence does not support the use of vertebroplasty
and this is likely to apply to other augmentation procedures
like kyphoplasty, although high-quality evidence from pla-
cebo-controlled trials are absent. In making quality, informed
patient care decisions, clinicians will need to balance the
limited findings on the safety and efficacy of other non-
pharmacologic interventions with good clinical judgment.
Fully disclosing the evidence to patients will ensure that they
can make the best evidence-informed decisions about their
care.
Fig. 1. Percutaneous vertebroplasty and balloon kyphoplasty.
Fig. 2. Spinomed back orthosis. (Reproduced with permission from
Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on
posture, trunk strength, and quality of life in women with postmeno-
pausal osteoporosis: a randomized trial. Am J Phys Med Rehabil.
2004;83:177–86. DOI: 10.1097/01.PHM.0000113403.16617.93.)
Journal of Bone and Mineral Research EFFICACY AND SAFETY OF VERTEBRAL AUGMENTATION 5
The Efficacy and Safety of Vertebral Augmenta-
tion: Task Force Recommendations and Findings
Vertebral compression fractures are highly prevalent in patients
with osteoporosis, and approximately 750,000 new fractures
occur each year in the United States alone.(1,2) Acute and chronic
back pain, occurring in approximately one-third of patients with
vertebral fractures, result in disability and impaired quality of life.
Pain from vertebral fractures may be managed through both
vertebral augmentation and nonpharmacological approaches.
Considering the increasing number of elderly individuals
conferred by population aging, vertebral fractures are antici-
pated to increase and, thus, current treatment strategies deserve
attention.
Vertebral augmentation is among the current standards of
care to reduce pain in patients with vertebral fractures, yet a
lack of consensus regarding efficacy and safety of percuta-
neous vertebroplasty and kyphoplasty raises questions, on
what basis clinicians should choose one therapy over
another. Of approximately 300,000 inpatient vertebral
augmentation procedures performed in the United States
between 2005 and 2010, 73% were kyphoplasty and 27%
were percutaneous vertebroplasty.(3) As patient outcomes for
these pain management strategies and nonpharmacological
approaches have not been compared to establish the relative
benefits and harms of these treatments, clinicians are left
with inadequate information to make decisions regarding
optimal patient care.
Given the lack of consensus in the field, ASBMR leadership
charged this Task Force to address key questions on the
efficacy and safety of vertebral augmentation and other
nonpharmacological approaches for the treatment of pain
Table 2. Summary of ASBMR Task Force Recommendations and Findings of Key Questions for Patients With Acutely Painful Vertebral
Fractures
Key question addressed
Task Force
recommendation/finding
Quality of
evidence Strength of findings
Strength of
recommendation
1. Efficacy of percutaneous
vertebroplasty on
outcomes of pain, physical
function, and quality of life
Percutaneous vertebroplasty
provides no demonstrable
clinically significant benefit over
placebo or sham procedure.
Results did not differ according to
duration of pain.
High to
moderate
High—5 randomized trials that
compared vertebroplasty with
placebo (n¼ 535). Follow-up
period 2 years.
High to
moderate
2. Efficacy of balloon
kyphoplasty on outcomes
of pain, physical function,
and quality of life
Balloon kyphoplasty provides a
small clinical benefit over
nonsurgical management,
percutaneous vertebroplasty,
vertebral body stenting, or KIVA.
There is also insufficient evidence
versus placebo for KIVA.
Low Low—1 randomized trial versus
nonsurgical management. No
placebo (n¼ 300). Follow-up
period 2 years.
Weak
3. Harms of percutaneous
vertebroplasty, including
possible risk of new
vertebral fractures
It is uncertain whether
percutaneous vertebroplasty
increases risk of incident or
radiographic vertebral fractures or
related serious AEs.
Moderate Moderate—8 randomized trials
(placebo control in 4 trials and
usual care in 4 trials) (n¼ 804). Low
number of events (n¼ 203
fractures; 57 SAEs). Follow up
period 1–2 years.
Moderate
4. Harms of balloon
kyphoplasty, including
possible risk of new
vertebral fractures
It is uncertain whether kyphoplasty
increases risk of incident or
radiographic vertebral fractures or
serious AE related to kyphoplasty.
Low Low—1 randomized trial versus
nonsurgical management (n¼ 223)
and case reports. Low number of
events (n¼ 101 fractures; 157
SAEs). Follow-up period 2 years.
Weak
5. Efficacy and harms of
spinal bracing after
vertebral fracture
It is uncertain whether spinal
bracing may improve physical
function, disability, or quality of
life.
Low Low—4 randomized trials
comparing orthoses (n¼ 281).
High risk of bias due to absent
blinding of subjects and
investigators. Low numbers of
fractures and AEs. Follow-up
period 3 weeks to 6 months.
Weak
6. Efficacy and harms of
exercise interventions after
vertebral fracture
Exercise may improve mobility and
reduce pain and fear of falling. It is
uncertain whether exercise
improves balance, back extensor
strength, reduces falls, and was
safe.
Moderate
to low
Low—9 randomized trials
comparing exercise with usual care
(n¼ 749). Low to high risk of bias
due to absent blinding of subjects
and investigators. Low numbers of
events (n¼ 15 fractures; 5 SAEs).
Follow-up period 4 weeks to 2
years.
Weak
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from acute vertebral fracture. It is important to note that
studies on pathological vertebral fractures were excluded. The
Task Force findings and recommendations are summarized
below.
Key Questions 1 and 2: What is the efficacy and relative
effectiveness of vertebral augmentation therapy in improv-
ing pain, posture, physical function, and quality of life?
Recommendation/finding: For patients with acutely
painful osteoporotic vertebral fracture, percutaneous
vertebroplasty provides no demonstrable clinically
important benefits compared with placebo or sham
procedure. There is insufficient evidence to support
kyphoplasty over nonsurgical management, percutane-
ous vertebroplasty, vertebral body stenting, or KIVA.
Table 3. Summary of ASBMR Task Force Recommendations for Future Research and Guidance on Clinical Management
Future research needed to improve patient outcomes in
managing osteoporotic vertebral fractures, either through
vertebral augmentation or other nonpharmacologic
approaches General research needs
• Future trials should identify other novel and potentially useful
interventions for pain after vertebral fracture.
• trials should ensure adequate sample sizes to answer the
research question.
• trials should have inclusion criteria that allow generalizable
conclusions to be drawn for the population that experiences
these acute vertebral fractures outside research settings.
• Include cost-effectiveness outcomes.
• anti-osteoporosis therapy as part of interventions.
• registries may be helpful for widespread systematic data
collection for safety after vertebral augmentation.
• More trials are needed exploring exercise or rehabilitation
interventions in the acute/subacute stage after vertebral fracture.
• Research on de-implementation of vertebroplasty to reduce
any potential harms of the procedure should be considered.
Percutaneous vertebroplasty and kyphoplasty • No further trials of vertebroplasty should be performed, unless
they are large and adequately powered to alter the conclusions
of the current body of evidence that concludes that the
procedure is no more effective than placebo and the benefits are
unlikely to outweigh any harms of the procedure.
• Any further trials of kyphoplasty should have a placebo control
group.
• More data are needed on potential harms, including new and
adjacent vertebral fractures, and cement leakage.
• Potential participants in any further trials of these procedures
should be fully informed about the current body of evidence.
• Ethics committees should also be fully informed about the
current body of evidence to inform their decision about the
ethics of any further trials.
Bracing and exercise interventions • More research is needed in nonsurgical interventions in
general, including more clearly defined participant selection
criteria and study protocols (including the frequency, intensity,
time, and type of intervention used).
• More rigorous trial design (eg, placebo procedure, blinding of
outcome assessors, use of validated outcome measures, patient
selection generalizable to clinical setting) is needed to reduce
bias potential and improve adherence and attrition.
Guidance for clinical management of patients with acute
vertebral fracture
• The optimal management of vertebral fracture is uncertain.
Routine use of vertebral augmentation is not supported by
current evidence. When it is offered, patients should be fully
informed about the evidence.
• Anti-osteoporotic medications must be initiated as soon as
practicable, or continued, in patients with a recent vertebral
fracture. A change in treatment may also need to be considered if
the vertebral fracture occurred after 12 months from initiation of
anti-osteoporotic treatment.
• Use of bracing in reducing pain immediately after vertebral
fracture is not supported by current evidence.
• Exercise may improve mobility and may reduce pain and fear of
falling. However, the use of exercise to improve other outcomes
is not supported by current evidence.
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Quality of evidence: Moderate to high for percutaneous
vertebroplasty; low for kyphoplasty
Strength of recommendation/finding: High for percuta-
neous vertebroplasty; weak for kyphoplasty
Evidence in support of recommendation/finding
1. Percutaneous vertebroplasty
Percutaneous vertebroplasty is a minimally invasive, fluoros-
copy-guided therapy used to relieve pain from an acute
vertebral fracture. It usually involves the percutaneous injection
of a bone cement, polymethylmethacrylate (PMMA), into the
vertebral body via the pedicle of the vertebra (Fig. 1). The aim of
this procedure is to reduce pain by stabilizing the vertebral
fracture.
This section is a summary and update of a recent systematic
review on percutaneous vertebroplasty for osteoporotic verte-
bral compression fracture.(5) Outcomes for percutaneous
vertebroplasty trials were compared with either placebo or
standard medical care.
a) Percutaneous vertebroplasty versus placebo
The updated Cochrane review included five randomized trials
that compared vertebroplasty with placebo.(6–12) Three trials
only included participants with pain for 9 weeks or less. Three
trials were considered to be at low risk of bias, whereas twowere
possibly at risk of performance and detection bias. There was
high-quality evidence that percutaneous vertebroplasty con-
ferred no clinically important benefits with respect to pain,
disability, or disease-specific quality of life, andmoderate quality
evidence of no important benefits for overall quality of life and
treatment success. Numerical data are presented for the 1-
month outcomes where available.
Efficacy findings are as follows:
Pain: At 1 month, there was a small and clinically unimportant
difference in pain favoring the vertebroplasty group (mean
difference [MD] –0.62 (95% CI –10.1 to –0.23) on a scale of 0 to
10, no statistical heterogeneity) (five trials, 535 participants).
Mean pain was five points in the placebo group and 0.6 points
better (0.2 to 1 better) in the vertebroplasty group. There were
also no between-group differences in the proportion of
participants who improved from baseline by 2.5 units or more
or by 30% or more at 1 month based upon pooled data from 3
trials (89/166 in the percutaneous vertebroplasty group versus
56/160 in the placebo group, risk ratio [RR] 1.53 [95% CI 0.99 to
2.36]), but there was substantial statistical heterogeneity
(I2¼ 61%). Based upon data from up to five trials (539
participants), no between-group differences in mean pain or
proportion who improved from baseline according to the above
parameters were observed at 1 to 2weeks or other endpoints up
to 2 years (Fig. 3).
Disability: Based upon four trials (472 participants), there was a
small and clinically unimportant difference in disability at
1 month favoring vertebroplasty (MD –1.50, 95% CI –2.61 to
–0.38), measured with the Roland Morris Disability Question-
naire (RMDQ) (0–23 scale, higher scores indicated greater
disability). Mean disability at 1 month (187 participants) in the
placebo group was 14.2 points, and 1.5 points better (0.4 better
to 2.6 better) in the vertebroplasty group, and there was no
Fig. 3. Forest plot of the efficacy outcome: vertebroplasty versus placebo (sham), pain (0 to 10 point scale)5.
8 EBELING ET AL. Journal of Bone and Mineral Research
statistical heterogeneity. There were no between-group differ-
ences in disability at any of the other time points based upon up
to four trials (475 participants).
Quality of life: Based upon three trials (351 participants), there
was no between-group difference in vertebral fracture and/or
osteoporosis-specific health-related quality of life as measured
by the QUALEFFO (0–100 scale, higher scores indicating worse
quality of life) at 1 month. Mean QUALEFFO was 62 points in the
placebo group and 2.3 points better in the vertebroplasty group
(1.4 points worse to 6.7 points better) (MD –2.33, 95% CI –6.06 to
1.41), I2¼ 36% indicating unimportant heterogeneity). There
were also no between-group differences at other time points
based upon up to three trials and 352 participants. Similarly,
there were no between-group differences in overall quality of
life at any time point up to 2 years (up to three trials and 285
participants).
Treatment success: One trial measured participant global
assessment of treatment success defined as “moderately better”
or “a great deal better” on a 7-point ordinal scale and observed
no between-group differences up to 24 months.(7,8) Specifically,
based upon 78 participants, at 1month 225 per 1000 in the sham
group and 315 per 1000 in the percutaneous vertebroplasty
group perceived treatment success (relative risk 1.40 [95% CI
0.67 to 2.95]).
b) Percutaneous vertebroplasty versus standard medical
(nonsurgical) care
There were eight trials that compared percutaneous vertebro-
plasty with standard medical care (1136 randomized partic-
ipants),(13–20) and they were considered sufficiently clinically
homogenous to allow data pooling. Trial participants had similar
levels of baseline pain and disability, and sex distribution was
also similar, although one trial included younger participants,(14)
and the duration of symptoms across trials varied from 1
week(17) to 6 months.(15)
Efficacy findings are as follows:
Pain: Based upon data from up to six trials, the analysis favored
the percutaneous vertebroplasty group, who had greater
improvement in mean pain compared with the usual care
group at 1 month (three trials, 384 participants, mean difference
–3.30 (95% CI –5.36 to –1.22). Similar results were observed at 1
to 2 weeks and at other time points up to 1 year, but there was
considerable statistical heterogeneity across all pooled pain
analyses with the I2 varying between 94% and 96%. At
24 months, there was no between-group difference in mean
pain based upon one trial.
Disability: Based upon data from up to five trials (494
participants), improvement in disability also favored the
percutaneous vertebroplasty group at all time points (MD at
1 month –6.38 (95% CI –12.60 to –0.17), three trials, 378
participants, I2¼ 97%). Considerable statistical heterogeneity
was also present for all other analyses (I2 ranging from 97% to
98%).
Quality of life: There was no significant between-group
differences with respect to vertebral fracture or osteoporosis-
specific quality of life at any time point measured by the
QUALEFFO up to 1 year, based upon data from up to 4 trials and
448 participants (1 month: two trials, 289 participants, mean
difference –10.18 (95% CI –21.49 to 1.13), I2¼ 95%). Consider-
able statistical heterogeneity was also present for all analyses (I2
varying between 83% and 95%). Overall quality of life measured
by the EQ-5D marginally favored the percutaneous vertebro-
plasty group at 1 month (one trial, 183 participants, mean
difference 0.09 [95% CI 0.01 to 0.16]). It also marginally favored
vertebroplasty at 1 to 2 weeks, 3 and 6 months, but not 1 year.
Statistical heterogeneity was unimportant for the pooled
analyses (I2 ranged from 0% to 22%).
Treatment success: This outcome was not reported in any of
the trials comparing percutaneous vertebroplasty with standard
care.
c) Subgroup analysis
The updated Cochrane review explored the effects of
vertebroplasty according to symptom duration (“acute” versus
“subacute”pain) in a subgroup analysis for outcomes of pain and
disability at 1 to 2 weeks and 1 month. Data for “acute” fractures
included trials that only included participants with pain less than
6 weeks,(8) 8 weeks or less,(10) or 9 weeks or less,(9) as well as the
participants with symptom duration of 6 weeks or less in two
other trials.(6,7) No important differences in outcomes were
found. Excluding data for the two trials, a longer duration of
“acute” fractures(9,10) did not alter the results.
d) Sensitivity analysis
Combining data for the five placebo-controlled trials with the
eight open trials that compared vertebroplasty with usual care
altered the results in favor of vertebroplasty for all end points
assessed in the sensitivity analysis (pain and disability at 1 to
2 weeks, 1 and 3 months). There was considerable heterogene-
ity, largely due to heterogeneity of results in the open trials.
Summary of percutaneous vertebroplasty
Based upon high- to moderate-quality evidence from five
randomized placebo-controlled trials, percutaneous vertebro-
plasty provides no demonstrable clinically important benefits
compared with placebo for people with acutely painful
osteoporotic vertebral fractures. Subgroup analyses in the
updated Cochrane review indicated that the results did not
differ according to duration of pain, whereas the sensitivity
analyses indicate that open trials that compared percutaneous
vertebroplasty with standard medical care are likely to have
overestimated any benefit of percutaneous vertebroplasty.
2. Balloon kyphoplasty
Balloon kyphoplasty is similar to percutaneous vertebroplasty
with the difference being that a balloon or bone tamp is
introduced via the vertebral pedicle into the vertebral body,
where it is inflated to create a cavity into which a percutaneous
injection of a bone cement, PMMA, is made (Fig. 1). This
procedure also aims to restore vertebral height and lessen spinal
deformity.
This section is an update on findings pertaining to balloon
kyphoplasty. A literature search was performed, and risk of bias
was assessed. Database searches yielded 2460 unique refer-
ences. We excluded 2406 during title and abstract review and 40
during full-text review, leaving 14 reports of 10 unique studies
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that met eligibility criteria and were included for analysis.(21–34)
Studies of vertebral fractures resulting from malignancy were
excluded. Among the 10 unique eligible studies, eight were
rated as having high risk of bias,(21,23–26,29–34) and twowere rated
as uncertain.(22,27,28) Themost common sources of bias were lack
of blinding, incomplete reporting of outcomes, and inadequate
or uncertain concealment of treatment allocation. However, it
would not have been possible to mask participants between
kyphoplasty and non-balloon kyphoplasty and surgical man-
agement without use of a sham procedure, or to mask assessors
of radiographic outcomes to the vertebral cement in the
kyphoplasty group. Further details regarding this review can be
found in the full report.(4)
The included studies compared kyphoplasty with nonsurgical
management, percutaneous vertebroplasty, another vertebral
augmentation device (KIVA®), and vertebral body stenting.
a) Balloon kyphoplasty versus nonsurgical management
Five RCTs (two unique trials) met eligibility criteria. The FREE trial
(n¼ 300)(23,24,30,33) used computer-generated permuted block
randomization, after which participants and study staff were
unblinded. Follow-up was 24 months. Yi and colleagues
(n¼ 200) stated participants were randomized, and treatment
assignment was blindly chosen by a single surgeon.(34) Outcome
assessors were blinded to treatment assignment, and follow-up
was 48 months. In the FREE trial, mean age was 72.2 years, and
77% of participants were female.(23,24,30,33) Qualifying vertebral
fractures were most commonly located at the thoracolumbar
junction and had occurred a mean of 6 weeks before
randomization. Vertebral fractures were attributed to osteopo-
rosis (40% of participants had a spine T-score <–2.5).(23,24,30) At
baseline, participants reported severe back pain (mean VAS 6.8
out of 10), substantial back-related disability (mean RMDQ score
17.5), and poor health-related quality of life (mean Short Form-
36 Physical Component Summary Scale [SF-36 PCS] score 25.7
and mean EQ-5D score 0.18). In Yi and colleagues,(34) mean age
was 61.3 years, and 62% were female. Qualifying vertebral
fractures were described as symptomatic. Prevalence of
osteoporosis was not specified, and no data were reported on
number of fractures per participant, fracture location, use of
bone active medications, or participant baseline pain, disability,
or quality of life.
Efficacy findings are as follows:
Pain: Kyphoplasty was associated with significantly more
reduction in pain than nonsurgical management at all time
points, though the relative difference between groups in
improvement in VAS appeared to diminish over time: mean
difference at 1 month¼ –1.82 [–2.37, –1.27; n¼ 264]; at 3
months¼ –1.45 [–2.01, –0.89; n¼ 246]; at 6 months¼ –1.48
[–2.05, –0.91; n¼ 241]; at 12 months¼ –0.84 [–1.42, –0.26;
n¼ 226]; and at 24 months¼ –0.69 [–1.27, –0.11; n¼ 200].
Disability: Kyphoplasty was associated with significantly more
reduction in the RMDQ scale than nonsurgical management at
30 days (–4.20 [–5.54, –2.86; n¼ 255]), 3 months (–3.69 [–5.10,
–2.28; n¼ 225]), 6 months (–3.05 [–4.50, –1.60; n¼ 230]), and
12 months (–2.90 [–4.37, –1.43; n¼ 204]) but not at 24 months
(–1.43 [–2.91, 0.05; n¼ 193]). The relative reduction in disability
after kyphoplasty compared with nonsurgical management also
appeared to diminish with time.
Quality of life: Kyphoplasty was associated with significantly
more improvement in the SF-36 score than nonsurgical
management at 1 month (5.40 [3.14, 7.66; n¼ 261]), 3 months
(4.00 [1.67, 6.33; n¼ 241]), and 6 months (3.30 [1.00, 5.60;
n¼ 237]) but not at 12 months (1.60 [–0.73, 3.93; n¼ 225]) or
24 months (1.50 [–0.83, 3.83; n¼ 186]). By comparison,
kyphoplasty was associated with significantly more improve-
ment than nonsurgical management on the EQ-5D at all time
points. For both of these outcomes, the difference between
groups diminished over time.
b) Balloon kyphoplasty versus percutaneous vertebroplasty
Six RCTs(25,27,28,31,32,34) (five unique trials, n¼ 857) and one quasi-
randomized study (n¼ 112)(26) met eligibility criteria. Two trials
were single-blinded,(32,34) two trials were unblinded,(25,31) and
two trials had no blinding specified.(26–28) Treatment allocation
was performed by computerized block randomization in two
studies,(25,27,28) assigned by the operating surgeon in two
studies,(26,34) and was not specified in two studies.(31,32) Follow-
up duration ranged from 6 to 60 months.(27,28)
The mean participant age was 71.6 years, and 75% were
female. Qualifying vertebral fractures were acute or subacute,
often less than 2 months old(25–28) with some studies requiring
supportive MRI findings.(25,26,32,34) Fractures were most com-
monly located near the thoracolumbar junction. Three studies
limited participation to individuals who had failed several weeks
of conservative therapy.(25,31,32) Three studies were limited to or
mostly comprised participants with osteopenia or osteoporo-
sis.(26,31,32) At baseline, participants reported severe back pain
(mean VAS range 7.6–8.1),(25–28,32) substantial back-related
disability (mean Oswestry Disability Index [ODI] range 58% to
66%),(25,26,32) and fair-to-poor quality of life (mean SF-36 PCS and
EQ-5D approximately 28 and 0.42, respectively).(25)
Efficacy findings are as follows:
Pain: In two RCTs, statistically significant, but small and likely to
be clinically unimportant, differences favored kyphoplasty over
percutaneous vertebroplasty at 1 month (VAS mean difference
¼ –0.28 [–0.43, –0.13]; n¼ 107, k¼ 1 trial)(32) and percutaneous
vertebroplasty over kyphoplasty at 5 years (mean difference:
0.60 [0.09, 1.11]; n¼ 100, k¼ 1 trial),(27) with no statistically
significant differences at other time points.(21,24,29) In the quasi-
randomized study, the mean difference in pain between
treatments was 0.60 [0.22, 0.98]; n¼ 86).(26)
Disability: In two RCTs(25,32) and one quasi-randomized
study,(26) there were no statistically significant differences
between treatments in improvement in ODI from baseline at
any time points ranging between 3 months and 2 years.
Quality of life: There was no statistically significant difference in
improvement in SF-36 PCS or EQ-5D between treatments at any
time point.
c) Balloon kyphoplasty versus KIVA®
Two eligible trials randomized participants to kyphoplasty versus
KIVA®.(22,29) KIVA® is aproprietary systemthatuses aflexible implant
made of amedical polymer to restore height to the vertebral body
and hold the cement. Inserting the implant requires an incision
about 1 cm in length, about the same size as with balloon
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kyphoplasty. Studies were single-blinded using a bipedicular
approach to surgery. Follow-up was 12 and 14 months, respec-
tively. Mean participant age was 73.7 years (72.8% female).
Efficacy findings were in the areas of pain, disability, and
quality of life. Treatment groups both had large improvements
in back pain (VAS) and back-related disability (ODI). One study
reported large improvements in both groups in quality of life
(SF-36 PCS).(22,29) However, there were no differences in the
magnitude of improvement in any of these outcomes at any
time point. There was no difference in risk of incident
radiographic vertebral fractures or incident adjacent radio-
graphic vertebral fractures after kyphoplasty versus KIVA®.(22,29)
There was no difference in serious AE between kyphoplasty and
KIVA® participants up to 12 months (34.6% versus 28.6%; 1.21;
0.84, 1.75; events¼ 80; n¼ 253).(22,29)
d) Balloon kyphoplasty versus vertebral body stenting
One eligible trial (n¼ 63, 100 treated levels) randomized
participants to kyphoplasty versus vertebral body stenting,
reporting only there were no neurologic sequelae in the
immediate postoperative period.(21)
Summary of balloon kyphoplasty
On average, individuals with painful vertebral fracture experi-
enced statistically significant symptomatic improvement com-
pared with baseline with all studied treatment interventions,
including nonsurgical management. Though we found that
kyphoplasty was associated with improved pain, back-related
disability, and quality-of-life outcomes compared with nonsur-
gical management, these results were derived almost entirely
from a single trial. Further, the magnitude of improvement from
baseline in these outcome measures after kyphoplasty relative
to nonsurgical management appeared to diminish over time,
and the mean between-group differences were smaller than
previously reported minimally clinically important differences
for individuals, raising concerns about their clinical significance.
Because we identified no eligible trials of kyphoplasty versus
sham kyphoplasty, it was not possible to determine to what
extent the observed improvements of kyphoplasty versus
nonsurgical management were attributable to a sham effect.
Compared with either percutaneous vertebroplasty or KIVA®,
there was no significant difference in pain, back-related
disability, or quality-of-life outcomes, although reductions in
kyphotic and increases in vertebral height were greater with
kyphoplasty compared with percutaneous vertebroplasty.
These results were limited by the lack of results reporting the
proportion of participants in each treatment group that
experienced a clinically important difference in each efficacy
outcome. The high risk of bias ratings of all the trials comparing
kyphoplasty versus percutaneous vertebroplasty further limits
confidence in these findings.
The current review was limited by available evidence. Though
10 unique trials met eligibility criteria, after considering the
different kyphoplasty treatment comparisons, outcome mea-
sures, and time points, only relatively few participants ultimately
provided information about the efficacy and safety of
kyphoplasty versus other interventions. Second, because all
but two trials reported results for efficacy outcomes only as
overall group means,(22,29) it was difficult to determine how
many and which types of participants achieved clinically
meaningful improvements with treatment. Third, AE and
incident vertebral fractures were rarely systematically reported
and often were not reported at all. Fourth, most trials were rated
as having high risk of bias, most commonly due to lack of
blinding of participants and/or outcome assessors and less often
due to a lack of allocation concealment, both which could have
led to overestimation of the true effect of interventions.
In summary, in middle-aged and older adults with vertebral
fracture on the basis of one study, kyphoplasty was associated
with greater improvement in pain, disability, and quality of life
than was nonsurgical management. Based on a small number of
heterogeneous (and high risk of bias) studies, there were no
differences in these outcomes between kyphoplasty and either
percutaneous vertebroplasty or KIVA. Any apparent benefits of
kyphoplasty over nonsurgical management appeared to
decrease over time, and, based on available data, it was not
possible to determine whether these between-group differ-
ences were clinically meaningful or the extent to which they
were accounted for by sham effects or study bias.
Key Questions 3 and 4. What are the harms of vertebral
augmentation therapy, including possible risk of new
vertebral fractures?
Recommendation/finding: Potential harmsand seriousAE
associated with vertebral augmentation therapy include
risk of death, incident vertebral fracture, cement leakage,
adjacent fractures, vasovagal reactions, cord compression
requiring immediate decompression, hypoxia, and respi-
ratory failure. It is uncertainwhether or not vertebroplasty
increases risk of incident or radiographic vertebral
fractures or serious AE related to percutaneous verte-
broplasty due to a low number of events and the
potential for bias. It is uncertain whether kyphoplasty
increases risk of incident or radiographic vertebral
fractures or serious AE related to kyphoplasty, despite
case reports, due to a lack of high-quality evidence.
Quality of evidence: Low for percutaneous vertebro-
plasty; low for kyphoplasty
Strength of recommendation/finding: Moderate for
percutaneous vertebroplasty; weak for kyphoplasty.
Evidence in support of recommendation/finding
1. Percutaneous vertebroplasty
a) Harms associated with percutaneous vertebroplasty for
new clinically or radiologically apparent vertebral fractures
Based upon low-quality evidence from six trials (control was
placebo for one trial and usual care for the other trials) with up to
12 to 24 months of follow-up, it is not certain whether
percutaneous vertebroplasty increases the risk of new symp-
tomatic vertebral fractures (48 fractures in 418 participants
(pooled incidence 95 per 1000; range 34 to 264) observed in the
percutaneous vertebroplasty group compared with 31 fractures
in 422 participants (pooled incidence 73 per 1000) in the control
group (RR 1.29 [95% CI 0.46 to 3.62]).(5,35,36) There was
substantial statistical heterogeneity (I2¼ 70%).
Based upon eight trials (placebo control in four trials and usual
care in four trials), it is also not certain whether vertebroplasty
increases the risk of new radiographic vertebral fractures
(vertebroplasty: 110 fractures in 411 participants (26.8%);
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control: 93 fractures in 393 participants (23.7%); RR 1.14 (95% CI
0.71 to 1.84). There was also substantial heterogeneity for this
analysis (I2¼ 67%) (Fig. 4).
b) Other serious AE reported with percutaneous
vertebroplasty
Based upon a pooled analysis of five trials (placebo control in
three trials and usual care in two trials), there were no significant
between-group differences in the number of other serious
adverse events (vertebroplasty: 16/408 [34 per 1000, range 18 to
62], control: 23/413; RR 0.61 [95% CI 0.33 to 1.10]). Excluding one
of the vertebroplasty versus usual care trials that reported
serious adverse events that appeared unrelated to the treatment
(ie, depression, pneumonia, sleep disturbance), the RR became
1.26 (95% CI 0.41 to 3.88). Serious AE related to percutaneous
vertebroplasty were reported in several trials. These included
osteomyelitis requiring surgical drainage, rib and pedicle
fractures, thecal sac injury, vasovagal reactions, acute asthma
exacerbation, cord compression requiring immediate decom-
pression, hypoxia, and respiratory failure. Cement leakage was
also reported to occur frequently (up to 78% of cases), but it was
not possible to determine the rate of significant sequelae arising
from cement leakage or embolism because of the small number
of events. Although most cases were asymptomatic, one trial(15)
reported an instance of cement leakage into the epidural space
requiring immediate decompression.
Summary of percutaneous vertebroplasty
Although the updated Cochrane review did not demonstrate an
increased risk of incident symptomatic vertebral fractures or
other serious AE associated with percutaneous vertebroplasty,
clinically important increased risks cannot be excluded because
of the small number of events.
2. Balloon kyphoplasty
a) Kyphoplasty versus nonsurgical management
Incident vertebral fractures: There was no significant differ-
ence between kyphoplasty and nonsurgical management
groups with regard to the risk of new-onset radiographic
vertebral fracture occurring at 3 months (21.9% versus 27.0%;
RR¼ 0.81 [0.51, 1.29; events¼ 54; n¼ 223]), 12 months (33.0%
versus 25.3%; 1.31 [0.85, 2.02; events¼ 62; n¼ 220]), or
24 months (47.5% versus 44.1%; 1.08 [0.81, 1.44; events¼ 101;
n¼ 220]). There was also no difference in incident adjacent
radiographic vertebral fracture (23.7% versus 16.7%; 1.54 [0.89,
2.65; events¼ 45; n¼ 220]) or incident clinical vertebral fracture
(20.8% versus 17.9%; 1.07 [0.69, 1.68; events¼ 58; n¼ 300]) at
24 months.(23,30,33,34)
AE: The FREE study reported a significantly increased risk of
any AE occurring within 1 month after kyphoplasty compared
with nonsurgical management (63.1% versus 36.4%; 1.73 [1.36,
2.21; events¼ 149; n¼ 300]) but not within 24 months (89.9%
versus 88.7%; 1.01 [0.94, 1.10; events¼ 268; n¼ 300]).(23,30,33)
There was no significant difference in risk of serious AE, either
within 1 month (16.1% versus 11.3%; 1.43 [0.80, 2.55;
events¼ 41; n¼ 300]) or 24 months of the intervention
(49.7% versus 48.3%; 1.03 [0.82, 1.29; events¼ 157;
n¼ 300]).(23,30,33)
b) Kyphoplasty versus percutaneous vertebroplasty
Incident vertebral fractures: There was no statistically
significant difference in risk of incident radiographic vertebral
fracture between treatments occurring within 1 month (15.2%
versus 17.9%; 0.85 [0.54, 1.33]; n¼ 381; k¼ 1 trial),(25) at 3months
(23.3% versus 27.4%, p¼ 0.43, k¼ 1),(25) 12 months (22.3%
versus 23.7%, p¼ 0.71, k¼ 2),(25,32) 24 months (49.1% versus
57.7%, p¼ 0.23, k¼ 1),(25) or 5 years (24.0% versus 20%, p> 0.05,
k¼ 1).(27) Similarly, there was no significant difference in risk of
incident adjacent radiographic vertebral fracture occurring after
12 months (11.3% versus 12.8%; 1.58 [0.79, 3.13]; n¼ 278;
k¼ 3),(27,28,31,32) and no significant difference in risk of incident
clinical vertebral fracture at 1 month (4.7% versus 8.9%; 0.53
[0.24, 1.15]) and 2 years (15.2% versus 17.9%; 0.76 [0.52, 1.10]) in
a single RCT,(25) or at 2 years in one quasi-randomized study
(18.2% versus 14.3%, 1.27 [0.48, 3.36], n¼ 86).(26) Comparedwith
percutaneous vertebroplasty, kyphoplasty also resulted in larger
reductions in kyphotic angle at 30 days, at 12 months, and after
12 months. Vertebral height also increased to a greater extent
Fig. 4. Forest plot of the safety outcome: vertebroplasty versus placebo (sham) or usual care, new radiographic vertebral fractures5.
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with kyphoplasty compared with percutaneous vertebroplasty
(data not shown).
AE: Only one study reported data on AE and found no increased
risk of AE at 30 days (0.70 [0.44, 1.11]; events¼ 63; n¼ 381) or
2 years (1.09 [0.49, 2.40]; events¼ 23; n¼ 281).(25)
Summary of balloon kyphoplasty
Compared with nonsurgical management, kyphoplasty was not
associated with a statistically significantly increased risk of
incident vertebral fracture, though CIs were wide, and results
could not exclude a clinically meaningful increase in risk. Further,
compared with nonsurgical management, kyphoplasty was
associated with a near doubling in risk of any AE within
30 days of intervention. Based on the mean between-group
differences in efficacy outcomes of uncertain clinical importance,
an increase in early AE, and the high risk of bias of the largest
eligible kyphoplasty versus nonsurgical management trial, it is
uncertainwhether anybenefits of kyphoplasty versusnonsurgical
management of vertebral fracture outweigh potential harms.
Compared with either percutaneous vertebroplasty or KIVA,
there was no significant difference in risk of incident vertebral
fracture or risk of any AE or serious AE with KP, although
reductions in kyphotic and increases in vertebral height were
greater with kyphoplasty compared with percutaneous verte-
broplasty. These results were limited by wide CIs around the
estimates for risk of incident vertebral fracture that could not
exclude clinically important differences in fracture risk and
limited reporting of AE outcomes. The high risk of bias ratings of
all the trials comparing kyphoplasty versus percutaneous
vertebroplasty further limits confidence in these findings.
A previous biased study reported on the incidence of new
vertebral fractures with uncertain results and, when compared
with other surgical techniques, kyphoplasty was associated with
similar reductions inpain.(37,38) Becausekyphoplasty is an invasive
procedure, there is concern that kyphoplasty may increase the
risk of new vertebral fractures at operated and adjacent levels.(39)
Adjacent fractures are reported to occur earlier than new-onset
fractures at the treated level (55 versus 127 days) with a RR of
4.62.(38) However, when kyphoplasty and percutaneous verte-
broplasty were compared, there was no significant difference in
incidenceof new-onset vertebral fractures.(37,39–41) Kyphoplasty is
associated with a 9% (81 in 1000 fracture level-years) risk of
epidural cement leakage, which may cause nerve-root injury.(42)
We showed a similar risk of AE (including cement leaks) and
serious AE in kyphoplasty and percutaneous vertebroplasty.
In summary, the current review was limited by available
evidence. AE and incident vertebral fractures were rarely
systematically reported and often were not reported at all. In
middle-aged and older adults with vertebral fracture on the
basis of one study, kyphoplasty was associated with an increase
in risk of early AE thanwas nonsurgical management. Based on a
single study, there was no difference in AE between kyphoplasty
and percutaneous vertebroplasty. Risks of subsequent fracture
were not statistically significantly different between kyphoplasty
and other treatments, but these results could not rule out
important differences.
3. Meta-analyses of vertebroplasty and kyphoplasty
Two recent meta-analyses examined the incidence of new
vertebral fractures after both vertebroplasty and kyphoplasty.
The first included 871 patients from seven randomized
controlled trials, of whom 436 received vertebral augmentation
treatment.(43) Numbers of new vertebral fractures in the two
groups were not significantly different. Six studies reported on
new adjacent vertebral fractures. As heterogeneity was identi-
fied among studies, two subgroups were created and a small
statistically significant increase in the incidence of new adjacent
vertebral fractures was found in the larger subgroup, which
comprised European trials. The second study included 1328
patients from 12 randomized controlled trials, clinical controlled
trials, and prospective clinical studies, of whom 768 received
vertebral augmentation treatment with either percutaneous
vertebroplasty or kyphoplasty.(44) No increases in the incidence
of either new vertebral or new adjacent vertebral fractures
compared with nonoperative management were found.
Key Questions 5 and 6. What is the efficacy and safety of
other nonpharmacologic treatments, such as spinal bracing
and exercise interventions after vertebral fracture?
Recommendation/finding: For patients with painful
vertebral fractures, there is limited evidence that spinal
bracing improves physical function, disability, or quality
of life. Exercise interventions can improve mobility, and
may improve pain, fear of falling, and back extensor
strength in individuals with vertebral fractures.
Quality of evidence: Low for bracing; low for exercise
interventions.
Strength of recommendation/finding:Weak for bracing;
weak for exercise interventions.
Evidence in support of recommendation/finding
There have been no trials comparing vertebral augmentation
with other nonsurgical interventions.
3. Spinal orthoses
Characteristics and outcomes of trials included in the analysis
are summarized in Table 4. Safety and efficacy findings are as
follows:
Pain: All four studies reported pain outcomes with improved
pain over time, but no trials suggested benefit between the
different types of braces used. In Pfeiffer and colleagues,(45)
there were no between-group differences in pain, but it should
be noted that the age of the vertebral fracture was not known.
Pfeiffer and colleagues(46) studied patients with vertebral
fracture diagnosed in the past 6 months and reported 38%
reduction in pain in the orthosis versus control groups. In the
setting of acute vertebral fracture, Kim and colleagues(47)
reported no significant change in VAS for pain in the control
versus either treatment group comparing a soft brace to a rigid
thoracolumbarsacral orthosis brace at 2, 6, and 12 weeks after
initiation of the bracing, though there was a trend toward pain
improvement in the rigid brace group. Li and colleagues(48)
reported significant improvements in pain in both orthoses
groups compared with control, but there were no significant
differences between the orthoses groups.
Disability/function: Kim and colleagues(47) studied the effects
of 8 weeks of bracing on ODI and reported no significant
Journal of Bone and Mineral Research EFFICACY AND SAFETY OF VERTEBRAL AUGMENTATION 13
Table 4. Characteristics and Outcomes of Studies Examining Spinal Orthoses for Fracture Management
Author, publication,
date, setting Patient characteristic Concomitant therapy Design
Major outcomes
and limitations
Kim et al., 2014 Tertiary
care, teaching hospital
Enrolled 0–3 days after
clinical OVF. Age 50
years. Total randomized:
60 patients; 41 female.
Acute single fracture.
Exclusion: >2 recent
fracture.
BAM not described.
Exercise: advice-injury
avoidance; allowed to
walk as desired
1:1:1 allocations. Control,
soft brace, rigid TSLO
brace (How Medicare,
Seoul, Korea). 8-week
continuous brace use
except when lying down.
Primary outcome: change
in ODI at 12 weeks.
Secondary outcomes:
change in VAS Pain Score
and in anterior vertebral
compression.
No significant change at
12 weeks in ODI for
control versus either or
soft brace. No significant
change in VAS for pain or
in vertebral body
compression ratio for
control versus either
treatment group. Results
potentially confounded
by higher baseline ODI
score for the rigid brace
group compared with
control and soft brace
group. There appears to
be a trend toward
improvement for ODI
and pain in the rigid
brace group.
Li et al., 2014 Inpatient
ward, teaching hospital
All subjects fitted with
custom-molded TSLO for
first week after acute OVF
for 24 hours per day. Age
55 years, mean age 82.
All female. Total
randomized: 51.
Cumulative fractures. 25
subjects with one
fracture, 16 with 2
fractures, 10 with 3 or
more fractures. Exclusion:
prior spine surgery or
severe spine DJD.
BAM not described.
Exercise protocol not
described.
Randomized starting at
week 1 to either soft
lumbar orthosis or
Spinomed orthosis
(MediBayreuth).
Spinomed orthosis worn
3 hours daily with soft
orthosis at other times.
Outcomes rated at end of
week 1 (baseline) and
week 3: VAS pain score,
gain in functional
mobility (FIM-motor
scores), EMS, Modified
Functional Ambulation
Category. Thoracic
kyphosis measured by X-
ray.
Improvement in all pain
and functional scores
between baseline and
week 3. No significant
difference between soft
lumbar brace and
Spinomed groups. No
difference in kyphosis
angle between groups
(only 5 subjects in each
group measured).
Pfeifer et al., 2011
Ambulatory, community
dwelling. Recruited
through newspaper
advertisement. Planned
RCT crossover study;
protocol revised at 6
months.
One OVF within the past
6 months and kyphosis
angle >60 degrees. Age
60 years, Mean age
72. All female. Average
of 2 vertebral fractures.
Total randomized: 108.
Exclusion: severe spinal
DJD.
BAM not described.
Exercise protocol not
described.
1:1:1 allocation among
control, Spinomed, and
Spinomed Active brace
(body suit with posterior
support rod). Brace worn
2 hours per day.
Originally planned
crossover at 6 months.
Treatment groups
refused due to perceived
efficacy and continued to
12 months. Control
group started Spinomed
brace at 6 months to
completion.
At 6 months, both brace
groups compared with
control showed
significant improvement
in back extensor muscle
strength and abdominal
flexor strength
(measured by Digi-Max,
mechaTronic, Germany),
body sway, kyphosis
angle, FEV1, pain
perception, and QoL. No
difference between brace
types. Nonsignificant
trend to further
improvement at
12 months.
Pfeifer et al., 2004
Ambulatory, community
dwelling. Prospective
randomized controlled
One or more vertebral
fractures. Enrollment
from time of fracture: not
specified. Angle of
BAM: All participants
received calcium,
vitamin D supplement,
and bisphosphonate.
Participants randomized
to control or Spinomed
orthosis for 6 months.
Orthosis to be worn 2
At 6 months, statistically
significant improvement
in isometric back
extensor muscle
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improvement at 12 weeks in either the rigid or soft brace group
compared with control. However, the rigid brace group had a
higher baseline ODI score than either the control or soft brace
group, which may have confounded the results. Another study
examined functional mobility pre- and post-bracing using
Functional Independence Measure-Motor Scores, Elderly Mobil-
ity scale, and Modified Functional Ambulation Category and
found that after 3 weeks of orthotic treatment, there was
significant improvement in all measures of functional mobility
but no difference between the Spinomed (Fig. 4) or soft lumbar
orthosis groups.(47) In other studies that assessed limitations of
daily living, there were improvements reported compared with
the control group at 6 months that were no longer significant at
1 year.(45,46)
Quality of life: One study compared general quality of life with
the SF-36 quality of life measure in the control (no brace), soft
brace, and rigid brace groups.(47) There were no significant
differences between the three groups for general health status
derived from the SF-36 physical and mental component scores
at 6 weeks and 12 weeks.
Posture/kyphosis: Pfeiffer and colleagues(45) reported a within-
group reduction of 7.9 4.9 degrees in kyphosis in the bracing
group versus a 1.6 5.5 degree reduction in kyphosis in the
control group that was significantly different between groups at
6 months (p¼ 0.02). The control group crossed over to wearing
the brace at 6 months, and kyphosis reduced significantly at
12 months in this group by 4.2 4.9 degrees, but the first
bracing group did not have any further improvement in
kyphosis at 12 months (1.9 4.1 degrees). In a later study,
Pfeiffer and colleagues(46) reported, coincidentally, the exact
same values as previously reported of a 7.9 4.9 degree
improvement in now 36, instead of 31, patients, who were
assigned to wear the Spinomed and an 8.1 10.5 degree
improvement in 36 patients assigned the Spinomed Active
brace, both values representing a significant within-group
reduction in kyphosis angle measured from standing
photomorphometry at 6 months (p< 0.01). After rigid bracing,
therewas no improvement in anterior/posterior vertebral height
ratio at 12 weeks, after 8 weeks of rigid bracing.(47) Li and
colleagues(48) described the effects of bracing on thoracic
kyphosis angle measured as Cobb angle (T5 to T12) from lateral
spine radiograph in a subset of 5 participants from each group:
the pretreatment kyphosis angle averaged 33 degrees (range
18–58) and posttreatment was 30.5 degrees (range 15–50).
However, these data are difficult to interpret, as one subject
decreased kyphosis from 58 to 32 degrees and another subject
increased kyphosis from 18 to 30 degrees, whereas 80% had
either no or relatively little change (within 5 degrees).
Performancemeasures:No trials includedmeasures of physical
mobility, although two trials included postural sway out-
comes.(45,46) One study reported significant differences between
the bracing group and control at 6 and 12 months in body sway
path length and velocity favoring the bracing group.(45) At
6 months, body sway path length (mm) reduced 20.4 40.2mm
in the intervention group versus 1.7 35.6mm in the control
group (p¼ 0.01). At 12 months, significant differences favored
the control group who had crossed over to wearing the brace,
although the results were confounded because 10% of the
subjects agreed to finish the 6-month intervention period,
whereas the remaining 28 subjects (90%) continuedwearing the
orthosis and were essentially followed over an intervention
period of 12 months total.
Muscle strength/endurance: One study compared muscle
performance outcomes after use of Spinomed and Spinomed
active orthoses to controls.(46) Compared with controls,
participants treated with either brace for 6 months had
improvement in back extensor muscle strength (64% to 72%)
and abdominal flexor strength (33% to 56%). With continued
brace usage, no further improvement in strength or mainte-
nance of improvement was observed at 12 months, leading the
authors to conclude that the effects of bracing were best
appreciated within the first 6 months of treatment.
Table 4. (Continued )
Author, publication,
date, setting Patient characteristic Concomitant therapy Design
Major outcomes
and limitations
crossover trial (crossover
not done because of
participant refusal).
Recruitment by
newspaper
advertisement.
kyphosis 60 degrees. All
females aged 60 years,
mean age 72. Total
randomized: 62.
Exclusion: advanced
spinal DJD.
Exercise protocol not
specified.
hours daily. Planned
crossover not done at
6 months because of
participant refusal.
Control group switched
to orthosis at 6 months.
Measurements as in
Pfeifer et al., 2011.
strength, abdominal
flexor strength, angle of
kyphosis, body sway and
sway velocity, FEV1, and
VC. Also improvement
compared with control in
pain relief, self-care, and
well-being. Additional
improvement at
12 months in back
extensor muscle strength
and abdominal flexor
strength. Trend to
improvement in angle of
kyphosis, VC, pain, and
limitations in daily living.
BAM¼bone-active medication; DJD¼degenerative joint disease; EMS¼ Elderly Mobility Scale; FEV1¼ forced expiratory volume in 1 second;
FIM¼ Functional Independence Measure; OVF¼ steoporotic vertebral fracture; QOL¼quality of life; RCT¼ randomized controlled trial; TLSO¼
thoracolumbosacral orthosis; VAS¼ visual analog scale; VC¼ vital capacity.
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Falls: No trial reported falls outcomes.
Global satisfaction with intervention: Only one study(47)
examined satisfaction with treatment during the follow-up
assessments and reported no differences among the three
groups (p¼ 0.42).
AE:NoAEwere reported in three of the four bracing trials. In one
study,(46) AE were not specifically reported, but 5 women
dropped out of the study because of either continued pain or
“low comfort.”
Risk of bias: One study was rated as unclear risk of bias due to
inadequate reporting of randomization, attrition, protocol, and
blinding procedures; one study was rated as low risk; and two as
high risk of bias. Blinding of participants was not possible for any
trials due to the nature of the intervention.
4. Exercise
Efficacy and safety findings are as follows:
Pain: Of the nine trials, four examined treatment effects in the
short term, ranging from 4 to 22 weeks, and results were mixed.
Exercise had no significant effect on pain outcomes after
4 weeks.(49) However, after a 10-week multimodal physical
therapy intervention that included exercise, Bennell and
colleagues(50) reported a significant clinically meaningful
between-group difference in favor of the intervention for pain
on movement (mean change score –1.8 points [95% CI –3.5 to
–0.1], p< 0.05) and pain at rest (mean change score –2.0 points
[95% CI –3.8 to –0.2], p< 0.05). Similarly, Wang and col-
leagues(51) reported a significant, but likely to be not clinically
meaningful, between-group difference in favor of the interven-
tion for pain (mean between-group difference in change scores
versus control –0.52, p¼ 0.001) after 4 weeks. One study
reported that supervised exercises for 10 weeks assessed at all
time points (5 weeks, 10 weeks, 22 weeks) demonstrated “a
significant difference between the course of values from the two
study groups (p¼ 0.02).”(52) However, when these results were
reanalyzed by the systematic review team as intention-to-treat
analysis, no significant effect on pain was observed at 4 weeks,
but only at 10 weeks was there a significant difference between
groups in favor of the intervention group for pain (mean
between-group change score –1.03 points [95% CI –1.37 to
–0.69], p¼ 0.013, not considered significant if using a Bonferroni
correction of six).
Similarly, conflicting data were observed for the two longer-
term studies that reported pain as an outcome with follow-up
ranging from 6 months to 2 years. For pain with activities, no
significant between-group difference was observed in 185
women with an average age of 81 who were enrolled based
upon having 1 vertebral fracture.(53) However, in a trial of 138
women aged in the late 60s, there was a reported significant
between-group difference in favor of the intervention for pain
after 24 weeks (mean between-group difference in change
scores versus control –0.72 points, p¼ 0.001), and after 52 weeks
(mean between-group difference in change scores versus
control –1.28 points, p¼ 0.001).
Disability/function: In general, shorter-term studies did not
report significant improvements in overall self-reported func-
tion, but there were small effects in some of the subscale
measures. For example, Bennell and colleagues(50) reported no
between-group difference in activity restriction but did report a
significant improvement in the physical function subscale of the
QUALEFFO-41 (mean between-group difference in change
scores –4.8 points [95% CI –9.2 to –0.5], p< 0.05) on a 0 to
100 scale, where lower scores indicate better physical function.
However, in a larger study of 89 women, there was no significant
improvement in the physical function subscale of the QUAL-
EFFO-41.(54) Two other studies reported no significant effect of
exercise after 4(52) and 10 weeks(51) on self-reported physical
function using the ODI or the Oswestry Low Back Pain
Questionnaire, respectively.
When examining the studies with longer follow-up of up to
2 years, there is a suggestion that the exercise interventions
may exert long-range effects that are not initially appreciated.
For example, in one study, there was no significant effect of
exercise at 6 months for physical function or activities of daily
living subscales of the Osteoporosis Quality of Life Question-
naire (OQLQ), but after 12 months, between-group differences
in the activities of daily living subscale of the OQLQ were
significant.(55) Another study favoring the exercise intervention
group reported a significant effect of exercise on the physical
function subscale of the QUALEFFO-41 at 1-year follow-up
(mean change score –2.5 points [95% CI –5.0 to –0.03] for the
intervention group versus –1.0 point [95% CI –1.5 to 3.4] for
the control group, effect size 0.3, p< 0.047).(54) Wang and
colleagues(51) also reported a significant between-group
difference in favor of the intervention for self-reported
physical function using the ODI after 6 and 12 months. Finally,
a recent study reported that the exercise intervention led to a
significant improvement in some subscales of the QUALLEFO-
41 questionnaire, including jobs around the house subscale
and mobility subscale, but no change in activities of daily
living subscale.(56) In summary, these data suggest inconsis-
tent benefits from small effects.
Quality of life: As was observed for functional outcomes, similar
results were observed favoring exercise interventions but only
upon longer follow-up times. After only 4 to 12 weeks of
exercise, most trials report no significant between-group
differences in total scores or subscales from disease-specific
quality of life outcomes,(50,54) with the exception of changes to
physical function subscale(50) or mental function subscale.(54)
The longer-term studies(55) reported significant improvements
in symptom, emotion, and leisure/social subscales, and the
differences in symptoms subscale persisted at 12 months.
Bergland and colleagues(54) reported a significant between-
group difference in total QUALEFFO-41 scores at 12-month
follow-up (mean change score –3.3 points [95% CI –5.2 to –1.3]
for the intervention group versus –0.4 points [95% CI –2.0 to
–2.7] for the control group, effect size 0.3, p< 0.019).
Evstigneeva and colleagues also found significant improve-
ments (p< 0.001) in the QUALEFFO-41 total score (mean change
score –5.8 points [95% CI –7.8, –3.8]) for the intervention group
versus the control group (mean change score 3.1 points [95% CI
1.3, 4.9]) and for pain, social function, and general health
perception subscales after 12 months of exercise.(56) In
summary, these data suggest inconsistent benefits from small
effects.
Only three studies used generic health-related quality-of-life
scales. Most report no significant between-group differen-
ces,(50,55) with the exception of one study,(54) which reported a
significant between-group difference for General Health
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Questionnaire total score (mean change score –3.7 points for the
intervention group [95% CI –5.5 to –1.9] versus –0.2 points for
the control group [95% CI –2.1 to 1.7], effect size 0.4, p< 0.009).
Posture/kyphosis: Three trials reported that exercise had no
statistically significant effect on posture outcomes.(50,56,57) No
other trials reported posture outcomes.
Performance measures: Several studies reported improved
mobility and balance after an exercise intervention. In one,
3months of exercise improvedmaximumwalking speed over 20
meters (mean change score –1.3 seconds [95% CI –2.0 to –0.6]
for the intervention group versus 0.6 seconds [95%CI –0.3 to 1.4]
for the control group, effect size 0.5, p< 0.001), a finding that
persisted 9months after cessation of intervention (p< 0.019).(54)
Other findings included improvement in time to get up from a
supine position (mean time 4.87 seconds [SD¼ 1.17] for the
intervention group versus 7.73 seconds [SD¼ 1.65] for the
control group, p< 0.001),(49) and improved Timed Up and Go
test, where data from three trials were pooled in ameta-analysis,
revealing a between-group difference of –1.09 seconds (95% CI
–1.78 to –0.40, p¼ 0.002) in favor of exercise.(49,50,54) Because
Bennell and colleagues(50) used a multimodal intervention, the
meta-analysis was also performed excluding data from this trial,
and the findings were similar. Discordant findings with respect
to effects of longer-term exercise programs on Timed Up and Go
performance exist. For example, whereas Evstigneeva and
colleagues(56) reported a significant improvement in Timed Up
and Go test performance (mean change score of –0.65 seconds
[95% CI –1.31, –0.10] for intervention group versus a mean
change score of 0.29 seconds [95% CI –0.37, 0.95] for control
group, p¼ 0.020), these data were not included in the meta-
analysis because of the large difference in follow-up time.
However, Papaioannou and colleagues(55) reported no signifi-
cant between-group differences for Timed Up and Go test
performance at 6 or 12 months. Data from this trial were not
included in the meta-analysis because the required parameters
were not available in the report or from the authors.
Estimates of the effect of exercise on measures of balance are
limited. No significant effect of exercise on postural sway was
observed after 22 weeks.(58) Functional reach was improved
(mean change score 1.7 cm [95% CI 0.1 to 3.1] after 3 months of
exercise for the intervention group versus –2.2 cm [95% CI –3.8
to –0.7] for the control group, effect size¼ 0.6, p< 0.001), but it
did not persist after cessation of intervention 9 months later.(54)
After 6 months of exercise, tests of postural sway revealed a
significant between-group difference in favor of exercise for the
range of displacement during the eyes closed condition (mean
change score –0.80 cm [95% CI –1.45 to –0.15], p¼ 0.01) but not
for any of the other postural sway variables.(55) After 12 months,
displacement in lateral and anteroposterior directions and
velocity of movement (measured with a force plate) were
significantly better in the intervention group compared with
control (p< 0.01), but no data were provided, and it is not clear if
this is for the eyes open or eyes closed condition.(55) Evstigneeva
and colleagues reported significant improvements in sit-to-
standweight transfer (mean change score –0.24 seconds [95%CI
–1.12, 0.64] for the intervention group versus 0.43 seconds [95%
CI 0.13, 0.73] for the control group, p¼ 0.010) and tandem walk
and sway tests (mean change score –0.08 degrees/s [95% CI
–1.62, 1.47] for the intervention group versus 1.72 [95% CI 0.15,
3.30] for the control group, p¼ 0.029).(56) However, no
significant between-group differences were observed for
sit-to-stand left/right weight symmetry and weight-bearing
squat tests.
Muscle strength/endurance: Exercise appears to improve back
muscle strength or endurance, as it is a consistent finding in
several studies, albeit not all of them. Bennell and colleagues(50)
observed a significant effect of a multimodal physical therapy
intervention including exercise for trunk muscle endurance
(mean change score in Timed Loaded Standing test of 46.7
seconds [95% CI 16.1 to 77.3], p< 0.05). In contrast, data from an
abstract(59) using the study sample from Gold and colleagues(53)
reported no between-group difference in change scores for
trunk and arm muscle endurance. No effect of exercise on back
extensor muscle strength was observed after 5 or 10 weeks;(58)
however, another study reported a significant between-group
difference in favor of exercise for trunk extension muscle
strength after 6 months of exercise (between-group difference
in change score 10.68 foot pounds [95% CI 6.98 to 14.39],
p< 0.001, n¼ 122, subgroup of total sample n¼ 185).(53)
Another study reported no significant difference in back
extensor muscle strength when control and intervention groups
were compared in intention-to-treat analyses (254 85N versus
302 108N, p¼ 0.74), but found a significant between-group
difference in back extensor muscle strength (p¼ 0.029) in a per-
protocol analysis, where 8 individuals who dropped out or were
not compliant with exercise or control activities were excluded,
and adjustment was made for baseline differences.(57)
Falls: No trial reported falls outcomes. Olsen and colleagues(60)
(an analysis of data from a prior trial(54)) reported a significant
between-group difference in favor of the intervention group for
Falls Self-Efficacy Scale-I score after 3 months and 12 months.
Fractures and bone mineral density: One study measured
fractures as a secondary outcome,(56) although studies were not
powered or designed with fracture as primary outcomes. During
the 12-month study, 4 participants in the exercise group
sustained clinical vertebral and nonvertebral fractures com-
pared with 7 participants in the control group (p¼ 0.285).
Another study reported four fractures as AE during exercise or
during assessments.(53) Effects of exercise interventions on bone
mineral density are discrepant. Papaioannou and colleagues
found no significant effect of thrice-weekly home exercise for
1 year on lumbar spine or femoral neck bone mineral density,(55)
whereas Wang and colleagues(51) reported a significant
between-group difference in favor of the intervention for
lumbar bone mineral density (mean between-group difference
in change scores versus control 0.038 g/cm2, p¼ 0.005) after
52 weeks.
AE: No studies specifically indicated that AE were included as an
outcome or described a method for assessing and recording AE
throughout the trial. Adverse events were reported in the results
section of four trials,(50,53,55–57) and one trial(52) indicated that
there were five AE unrelated to study participation but did not
describe them. Five events, including two fractures, were
directly attributable to exercise (see above). Details are
published elsewhere.(61)
Risk of bias: Four trials were rated as low risk of bias,(50,52–54)
four as unclear risk of bias,(49,51,55,56) and one as high risk of
bias.(57) Blinding of participants was not possible for any trials
because of the nature of the intervention.
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Summary of nonpharmacologic interventions
Four studies of low quality considered spinal bracing after
vertebral fracture in both acute and chronic settings. Evidence
that spinal bracing affected rate of incident vertebral fracture
was lacking. Three trials suggested backpack thoracolumbar
orthosis, lumbosacral orthosis, or a garment orthosis worn 2
hours a day may reduce self-reported pain at 6 months, and the
choice of orthosis did not matter. Backpack thoracolumbosacral
orthosis and a garment orthosis may benefit trunk muscle
strength and reduce thoracic kyphosis at 6 months. There is no
evidence that spinal bracing improves quality of life, physical
function, or disability.
Although there was substantial variability in study designs
and interventions, the current evidence suggests that exercise
interventions have significant positive effects on mobility and
may improve pain, fear of falling, and back extensor strength.
However, the magnitude of effects on mobility was small (eg,
between-group differences approximately 1 second for Timed
Up and Go and approximately 2 seconds for walking speed).
Improvements in back extensor strength or endurance was
reported across several trials, but no trials reported improve-
ments in posture. However, available data are limited. Trials
that had pain as an inclusion criterion reported significant
reductions in pain with exercise, a finding that should be
interpreted with caution given the lack of blinding of
participants and self-reporting. Exercise may have an effect
on disease-specific quality-of-life outcomes but only among
interventions that were longer than 12 weeks in duration.
Fractures attributable to either intervention or assessment
occurred, but some were during transitions and not the
exercises, indicating individuals with vertebral fractures need
to learn how to safely perform both the exercises and
transitions between exercises.
Key Question 7. What research is needed to fill knowledge
gaps to improve patient outcomes in managing osteopo-
rotic vertebral fractures, either through vertebral augmen-
tation or other nonpharmacologic approaches?
Recommendation/finding: General and intervention-
specific research recommendations stress the need to
reduce study bias and address methodological flaws in
study design and data collection. This includes the need
for larger sample sizes, inclusion of a sham control, more
data on serious AE, and more research on nonpharma-
cologic interventions.
Several suggestions for future research are listed below,
organized by general recommendations that apply to all
studies, and then recommendations specific to studies of
percutaneous vertebroplasty, balloon kyphoplasty, and brac-
ing or exercise.
General recommendations for all future studies
 Future trials should identify other novel and potentially
useful interventions for pain after vertebral fracture.
 Future trials should ensure adequate sample sizes to answer
the research question.
 Future trials should have inclusion criteria that allow
generalizable conclusions to be drawn.
 Include cost-effectiveness outcomes.
 Include anti-osteoporosis therapy as part of interventions.
 Patient registries may be helpful for widespread systematic
data collection for safety after vertebral augmentation.
 More trials are needed exploring exercise or rehabilitation
interventions in the acute/subacute stage after vertebral
fracture.
 De-implementation of vertebroplasty to reduce any poten-
tial harms of the procedure should be considered by
translating evidence into changes in practice and policy.
 All future studies should consider including outcomes
important to people with osteoporotic spine fracture(s),
health care providers, or health systems, such as quality of
life, pain, falls, fractures, and disability.
 Future trials should include men.
 Future studies should consider the relative benefit of short-
term versus long-term improvements. If short-term im-
provements are substantial, this might be sufficient to
warrant the treatment even if long-term outcomes are
similar. Impact of the intervention on disability also should
be considered over the short term and long term.
 Registries should be established to systematically collect
safety data on patients treatedwith vertebral augmentation.
 More trials are needed exploring exercise or rehabilitation
interventions in the acute/subacute stage after vertebral
fracture.
Percutaneous vertebroplasty
 No further trials of vertebroplasty should be performed,
unless they are adequately powered to alter the conclusions
of the current body of evidence that concludes that the
procedure is no more effective than placebo and the
benefits are unlikely to outweigh any harms of the
procedure.
 Potential participants in any further trials of these proce-
dures should be fully informed about the current body of
evidence.
 Ethics committees should also be fully informed about the
current body of evidence to inform their decision about the
ethics of any further trials.
 All future trials should include strategies designed to
minimize the potential for bias, including adequate alloca-
tion concealment, use of a realistic placebo intervention,
and blinding of both participants and investigators to the
intervention.
 Future trials should carefully characterize the timing and
severity of vertebral fracture among study participants.
Balloon kyphoplasty
 Any further trials of kyphoplasty should have a placebo
control group.
 Further studies are needed to resolve whether kyphoplasty
increases the risk of future vertebral fractures or serious AE,
which should be systematically collected.
 All future trials should include strategies designed to
minimize the potential for bias, including adequate alloca-
tion concealment, use of a realistic placebo intervention,
and blinding of both participants and investigators to the
intervention.
 Future trials should carefully characterize the timing and
severity of vertebral fracture among study participants.
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Bracing/exercise
 More research is needed in nonpharmacological interven-
tions in general, including more clearly defined participant
selection criteria and study protocols (including the
frequency, intensity, time from acute vertebral fracture,
number of vertebral fractures, and type of intervention
used).
 More rigorous trial design is needed to reduce bias potential
and improve adherence and attrition.
 More data are needed on serious AE in the intervention and
compactor groups to ensure that harms of a nonpharmaco-
logical intervention do not outweigh any benefits.
 Few trials examine the efficacy of exercise after acute
vertebral fracture, so this is an area where more research is
needed.
 Future studies assessing the efficacy of nonpharmacological
interventions should clearly define:
 The type of brace (for bracing studies).
 The frequency, intensity, time, and type of exercise(s)
prescribed; therapeutic goals; physical therapy inter-
ventions; and methods of delivery (for exercise or
physical therapy interventions).
 Future exercise trial design should account for low
adherence and attrition in sample size calculations. Adher-
ence appears to be higher among studies that include
supervised, patient-specific assessment and prescription,
even if it is intermittent.
Guidance for clinical management of patients with acute
vertebral fracture
Recommendations/finding:
 The optimal management of vertebral fracture is uncertain.
Routine use of vertebral augmentation is not supported by
current evidence. When it is offered, patients should be fully
informed about the evidence.
 Anti-osteoporotic medications must be initiated as soon as
practicable, or continued, in patients with a recent vertebral
fracture. A change in treatment may also need to be
considered if the vertebral fracture occurred after 12months
from initiation of anti-osteoporotic treatment.
 Use of bracing in reducing pain immediately after vertebral
fracture is not supported by current evidence.
 Exercise may improve mobility and may reduce pain and
fear of falling. However, the use of exercise to improve other
outcomes, including falls and fractures, is not supported by
current evidence.
Based on the recommendations and findings in this report,
the ASBMR Task Force offers the following guidelines for the
clinical management of patients with vertebral fracture.
Vertebral augmentation
 In the majority of patients, pain from a vertebral fracture
diminishes with time. Based on the available evidence,
in patients with acutely painful vertebral fractures,
percutaneous vertebroplasty provide no demonstrable
clinically significant benefit over placebo or sham
procedure.
 As head-to-head trials have not found significant
benefits of kyphoplasty over vertebroplasty with
respect to pain, disability, or quality of life, it is unlikely
that kyphoplasty would have benefits over placebo, but
no placebo-controlled trials of kyphoplasty have been
performed.
 The optimal management of patients with acute
vertebral fracture remains uncertain.
 Routine use of vertebral augmentation for pain relief
after vertebral fracture is not supported by current data.
 It is critical that anti-osteoporotic medications are
started, continued, or changed (in the case of treatment
failure) in patients with recent vertebral fracture. Data
from several randomized controlled trials indicate anti-
osteoporosis medications reduce the risk of subsequent
vertebral fractures by 40% to 70%.
Bracing/exercise
 Only four randomized controlled trials of variable quality
examined the effects of hard and soft types of bracing for
individuals with vertebral fractures. The benefits of
wearing a rigid or soft bracing in the acute stage (3 to
12 weeks after acute vertebral fracture) are contradic-
tory regarding pain and disability outcomes, making it
difficult to recommend bracing in the acute phase.
However, based upon limited evidence, there appears to
be a benefit of bracing on pain and possibly other
outcomes of spine strength, kyphosis angle, pulmonary
volume, and quality of life from backpack thoracolum-
bar orthosis, lumbosacral orthosis, or a garment orthosis
worn 2 hours a day over 6 months among individuals
within 6 months of onset of a vertebral fracture. The
choice of orthosis does not matter.
 The majority of studies of exercise in individuals with
vertebral fractures have not recruited individuals with
acute fractures, so the evidence is indirect. Many of the
exercise programs were center-based and supervised by a
physical therapist; setting and level of supervision may
influence adherence or outcomes.
 Exercise may improvemobility and reduce pain and fear
of falling in those who have pain due to vertebral
fracture. Individual trials did report benefits for some
outcome measures, including physical function, balance,
back extensor muscle strength, trunk muscle endurance,
quality of life, bonemineral density, and fear of falling. These
findings should be interpreted with caution given the small
number of trials and the heterogeneity in the direction and
estimates of effects.
 All of the trials’ exercise programs included muscle
strengthening, andmany included back extensor muscle
exercises (targetingstrengthorendurance). Therefore, to
achieve the potential benefits suggested by any of the
trials, these should be included in the exercise prescrip-
tion. In the presence of pain due to vertebral fracture, it may
be advisable initially to perform exercises targeting back
extensors or spine stabilizers in an unloaded position, such
as supine, and then progressing the difficulty of the exercise
according to tolerance. Examples include unilateral thoracic
extension via supine shoulder flexion 180 degrees; gentle
“press” of shoulders into floor while lying supine; or lumbar
extension via unilateral activation of hip extensors pressing
leg into floor while supine.
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